Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Kinnate Biopharma Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "SAN FRANCISCO and SAN DIEGO – August 8, 2023 –"
07/28/2023 8-K Quarterly results
06/12/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 8-K Quarterly results
Docs: "Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates"
04/17/2023 8-K Quarterly results
03/15/2023 8-K Quarterly results
Docs: "Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates"
01/26/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/11/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Company anticipates sharing detailed dose escalation data in the first half of 2023"
08/11/2022 8-K Quarterly results
06/15/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/28/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "SAN FRANCISCO and SAN DIEGO, Calif. – March 28, 2022 – Kinnate Biopharma Inc. , a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the full year ended December 31, 2021. “The continuing advancement across our pipeline last year, including the first patient being dosed in our Phase 1 trial evaluating KIN-2787 in adult patients with BRAF-mutant advanced and metastatic tumors, positions the company to further deliver on several key upcoming milestones in 2022,” said Nima Farzan, Chief Executive Officer of Kinnate Biopharma. “For KIN-2787, we are on target to report initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third ..."
01/18/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SAN FRANCISCO and SAN DIEGO, January 18, 2022 -- Kinnate Biopharma Inc. , a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the U.S Food and Drug Administration has cleared the company’s Investigational New Drug application for KIN-3248, a next-generation pan-FGFR inhibitor being developed for intrahepatic cholangiocarcinoma and urothelial carcinoma ."
01/06/2022 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "SAN FRANCISCO and SAN DIEGO, Calif. – January 06, 2022 – Kinnate Biopharma Inc. , a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced continued advancement of the company’s ongoing clinical trial, KN-8701, to include patients with NRAS-mutant melanoma and planned 2022 milestones for its product candidates, including KIN-2787, an orally available small molecule pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors. The company also updated its cash position as of December 31, 2021."
01/03/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
11/10/2021 8-K Quarterly results
Docs: "SAN FRANCISCO and SAN DIEGO, Calif. – November 10, 2021 – Kinnate Biopharma Inc. , a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the quarter ended September 30, 2021."
10/28/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "SAN FRANCISCO and SAN DIEGO, Calif. – October 28, 2021 – Kinnate Biopharma Inc. , a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the company’s Chief Scientific Officer, Eric Murphy, Ph.D., will step down from that role on December 3, 2021 to pursue a new opportunity. Dr. Murphy will remain an important scientific adviser to Kinnate and will continue to support the company by serving on its Scientific Advisory Board."
08/16/2021 8-K Quarterly results
Docs: "SAN FRANCISCO and SAN DIEGO, Calif. – August 16, 2021 – Kinnate Biopharma Inc. , a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced financial results for the quarter ended June 30, 2021. The company also announced that the first patient has commenced treatment in its Phase 1 KN-8701 clinical trial evaluating its lead RAF product candidate, KIN-2787, a pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma and other solid tumors."
06/28/2021 8-K Quarterly results
06/15/2021 8-K Quarterly results
06/07/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/29/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy